In addition to our own internal develop work, we will work with collaborators and academia to further understand the potential clinical utility and mechanism of tRNA synthetase biology. We plan to leverage our discovery engine to identify other tRNA synthetase pathways of interest and select additional product candidates for preclinical and clinical investigation in a variety of disease settings through a combination of efforts between ourselves, Pangu Biopharma Ltd., our subsidiary, and the Scripps Research Institute.
We believe our strategy of understanding extracellular tRNA synthetase function by using in vivo experiments early and often while using patient data to focus this in vivo exploration has been validated by our early-stage clinical programs. Additionally, we believe our discovery engine can be applied to other members of the tRNA synthetase family to help identify additional clinical utility.
We believe this new biology presents novel protein therapeutic development opportunities based on the modulation of important immunological pathways applicable to multiple diseases. In addition to our own internal development work, we will work with collaborators and academia to further understand the potential clinical utility and mechanism of tRNA synthetase biology.
Click here to learn more about our ongoing collaborations.